SG10201805622QA - Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides - Google Patents
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of PolypeptidesInfo
- Publication number
- SG10201805622QA SG10201805622QA SG10201805622QA SG10201805622QA SG10201805622QA SG 10201805622Q A SG10201805622Q A SG 10201805622QA SG 10201805622Q A SG10201805622Q A SG 10201805622QA SG 10201805622Q A SG10201805622Q A SG 10201805622QA SG 10201805622Q A SG10201805622Q A SG 10201805622QA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptides
- expression vector
- expression cassette
- cell generation
- generation methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides Herein is reported an expression vector comprising 5 - an antibody light chain expression cassette, - an antibody heavy chain expression cassette, and - a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5’ to 3’ sequence of antibody 10 heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies. 15 [Fig. 9]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11195363 | 2011-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201805622QA true SG10201805622QA (en) | 2018-08-30 |
Family
ID=47557065
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805622QA SG10201805622QA (en) | 2011-12-22 | 2012-12-19 | Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides |
SG10201601882PA SG10201601882PA (en) | 2011-12-22 | 2012-12-19 | Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides |
SG11201403223PA SG11201403223PA (en) | 2011-12-22 | 2012-12-19 | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201601882PA SG10201601882PA (en) | 2011-12-22 | 2012-12-19 | Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides |
SG11201403223PA SG11201403223PA (en) | 2011-12-22 | 2012-12-19 | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
Country Status (16)
Country | Link |
---|---|
US (3) | US9963511B2 (en) |
EP (2) | EP3816284A1 (en) |
JP (4) | JP2015502165A (en) |
KR (3) | KR102080356B1 (en) |
CN (2) | CN107881196A (en) |
BR (1) | BR112014012667A2 (en) |
CA (2) | CA3125875A1 (en) |
ES (1) | ES2791758T3 (en) |
HK (2) | HK1203546A1 (en) |
HR (1) | HRP20200744T1 (en) |
MX (1) | MX355625B (en) |
PL (1) | PL2794878T3 (en) |
RU (2) | RU2628703C2 (en) |
SG (3) | SG10201805622QA (en) |
SI (1) | SI2794878T1 (en) |
WO (1) | WO2013092723A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2794878T3 (en) * | 2011-12-22 | 2020-07-27 | F.Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
EP3183351A2 (en) | 2014-07-18 | 2017-06-28 | Celltheon Corporation | Methods and compositions for expression of polypeptides in a cell |
SG11202103334YA (en) * | 2018-10-26 | 2021-05-28 | Hoffmann La Roche | Multispecific antibody screening method using recombinase mediated cassette exchange |
CN112626121B (en) * | 2020-12-29 | 2024-04-09 | 苏州博腾生物制药有限公司 | Antibody expression vector of triple screening mark and application thereof |
CN113512537A (en) * | 2021-08-19 | 2021-10-19 | 长春生物制品研究所有限责任公司 | Recombinant CHO cell strain for high expression of human follicle stimulating hormone and construction method thereof |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3584341D1 (en) | 1984-08-24 | 1991-11-14 | Upjohn Co | RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA. |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
JP3051411B2 (en) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | Novel DNA and expression plasmid containing it |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6207455B1 (en) * | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
JP2002506353A (en) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
JP2001521909A (en) | 1997-10-31 | 2001-11-13 | ジェネンテク・インコーポレイテッド | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
DE69942021D1 (en) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODY-DEPENDENT CELL-EMITTED CYTOTOXICITY |
JP2002525047A (en) * | 1998-09-16 | 2002-08-13 | ネクシア バイオテクノロジーズ, インコーポレイテッド | Production of recombinant protein in urine |
KR20000046969A (en) | 1998-12-31 | 2000-07-25 | 이선경 | Eukaryotic cell expressing vector containing a expression regulating factor derived from the heterologous genes with the strong transcription activity |
DK2270149T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE. |
DE60022369T2 (en) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | PROCESS FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
KR100767146B1 (en) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Humanized Antibodies That Sequester Amyloid Beta Peptide |
JP2003531588A (en) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | Multivalent antibodies and their uses |
AU2001261628A1 (en) * | 2000-05-16 | 2001-11-26 | Euroceltique S.A. | Cd28 synthebody for the modulation of immune responses |
KR100408844B1 (en) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | Expression vector using for animal cell |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CN102311986B (en) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | Produce the cell of antibody compositions |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3797974B2 (en) * | 2000-11-17 | 2006-07-19 | ヘマテック,エルエルシー | Expression of heterologous (human) immunoglobulins in cloned transgenic ungulates |
DE60131456T2 (en) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | TRANCHROMOSOMAL TRANSGEN RODENTS FOR THE MANUFACTURE OF HUMAN ANTIBODIES |
IL157142A0 (en) | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
CA2450019A1 (en) * | 2001-06-08 | 2002-12-19 | Icon Genetics, Inc. | Production of proteins in plants |
NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
NZ532060A (en) * | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
HUP0402164A3 (en) | 2001-11-16 | 2010-01-28 | Biogen Idec Inc | Polycistronic expression of antibodies |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20030215858A1 (en) | 2002-04-08 | 2003-11-20 | Baylor College Of Medicine | Enhanced gene expression system |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa |
WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
WO2003085118A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
KR20070055625A (en) | 2002-12-16 | 2007-05-30 | 제넨테크, 인크. | Immunoglobulin variants and uses thereof |
MXPA05006724A (en) | 2003-01-07 | 2005-09-08 | Symphogen As | Method for manufacturing recombinant polyclonal proteins. |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
JP4685764B2 (en) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | Modification of antibody FcRn binding affinity or serum half-life by mutagenesis |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
JPWO2005035586A1 (en) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Fusion protein composition |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF a1,6-FUCOSYLTRANSFERASE |
LT2348051T (en) | 2003-11-05 | 2019-02-25 | Roche Glycart Ag | CD20 antibodies with increased fc receptor binding affinity and effector function |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
KR20070004026A (en) * | 2004-03-15 | 2007-01-05 | 비오겐 아이덱 엠에이 아이엔씨. | Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing |
WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
KR100891620B1 (en) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | Anti-p-selectin antibodies |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
US8076102B2 (en) | 2005-05-18 | 2011-12-13 | Biofactura, Inc. | Compositions and methods for metabolic selection of transfected cells |
ATE505552T1 (en) | 2005-10-21 | 2011-04-15 | Hoffmann La Roche | METHOD FOR RECOMBINANT EXPRESSION OF A POLYEPTIDE |
ES2577292T3 (en) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Binding polypeptides with diversified VH / VL hypervariable sequences and consensus |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
PL2059533T3 (en) | 2006-08-30 | 2013-04-30 | Genentech Inc | Multispecific antibodies |
CA2672979A1 (en) | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Selection method |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100999732A (en) * | 2006-12-30 | 2007-07-18 | 北京济普霖生物技术有限公司 | Process of producing anti-humen CD20 monoclone antibody by animal mammary gland |
BRPI0809361A2 (en) | 2007-03-30 | 2014-09-02 | Abbott Lab | RECOMBINANT EXPRESSION VECTOR (REVES) ELEMENTS TO IMPROVE EXPRESSION OF RECOMBINANT PROTEINS IN HOST CELLS |
EP1995309A1 (en) * | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
RU2491344C2 (en) | 2007-06-29 | 2013-08-27 | Ф.Хоффманн-Ля Рош Аг | Promoter |
EP2207881A1 (en) | 2007-10-12 | 2010-07-21 | F. Hoffmann-Roche AG | Protein expression from multiple nucleic acids |
BRPI0821311B1 (en) | 2007-12-21 | 2018-09-18 | Novartis Ag | LINEARIZED VECTOR NUCLEIC ACID, METHOD FOR PRODUCTION OF A MAMMALIAN HOST CELL UNDERSTANDING SUCH ACID, AND METHOD FOR PRODUCTION OF A POLYPETIDE OF INTEREST |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
SI2235064T1 (en) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
CN101550425B (en) * | 2008-03-31 | 2011-03-30 | 北京大学 | Method for manufacturing adjustable liver injury animal model and special carriers thereof |
CN112481300A (en) | 2008-06-27 | 2021-03-12 | 莫鲁斯股份有限公司 | Non-human mammal producing antibodies |
CA2734340C (en) | 2008-08-28 | 2019-03-05 | Novartis Ag | Cell surface display of polypeptide isoforms by stop codon readthrough |
GB0903207D0 (en) | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
PE20120591A1 (en) | 2009-04-02 | 2012-05-23 | Roche Glycart Ag | MULTI-SPECIFIC ANTIBODIES INCLUDING FULL-LENGTH ANTIBODIES AND SINGLE-CHAIN FAB FRAGMENTS |
PL2417156T3 (en) | 2009-04-07 | 2015-07-31 | Roche Glycart Ag | Trivalent, bispecific antibodies |
JP5719354B2 (en) | 2009-05-27 | 2015-05-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Triple or quadrispecific antibody |
JP4547643B1 (en) * | 2009-06-05 | 2010-09-22 | 東洋紡績株式会社 | Expression vector optimized for cloning |
JP4525863B1 (en) | 2009-06-05 | 2010-08-18 | 東洋紡績株式会社 | Expression vector for establishment of high-productivity cells and high-productivity cells |
CN101596316A (en) * | 2009-06-12 | 2009-12-09 | 长沙新生康源生物医药有限公司 | Express recombinant adenovirus and the application in oncotherapy and prevention thereof of FoxM1siRNA |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
KR20120099376A (en) * | 2009-09-18 | 2012-09-10 | 셀렉시스 에스. 에이. | Products and methods for enhanced transgene expression and processing |
JP5506339B2 (en) | 2009-11-19 | 2014-05-28 | 三菱重工業株式会社 | Direction control device and direction control method |
JP2013541937A (en) * | 2010-08-05 | 2013-11-21 | エフ.ホフマン−ラ ロシュ アーゲー | Anti-MHC antibody-antiviral cytokine fusion protein |
SG191124A1 (en) * | 2010-12-15 | 2013-07-31 | Kek High Energy Accelerator | Protein production method |
PL2794878T3 (en) * | 2011-12-22 | 2020-07-27 | F.Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
EP3083676B1 (en) * | 2013-12-20 | 2019-08-28 | Novartis AG | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
-
2012
- 2012-12-19 PL PL12813822T patent/PL2794878T3/en unknown
- 2012-12-19 KR KR1020147016980A patent/KR102080356B1/en active IP Right Grant
- 2012-12-19 SI SI201231777T patent/SI2794878T1/en unknown
- 2012-12-19 JP JP2014547978A patent/JP2015502165A/en active Pending
- 2012-12-19 MX MX2014007360A patent/MX355625B/en active IP Right Grant
- 2012-12-19 US US14/367,043 patent/US9963511B2/en active Active
- 2012-12-19 CA CA3125875A patent/CA3125875A1/en active Pending
- 2012-12-19 KR KR1020207000703A patent/KR102184059B1/en active IP Right Grant
- 2012-12-19 CA CA2853955A patent/CA2853955C/en active Active
- 2012-12-19 SG SG10201805622QA patent/SG10201805622QA/en unknown
- 2012-12-19 ES ES12813822T patent/ES2791758T3/en active Active
- 2012-12-19 EP EP20163218.9A patent/EP3816284A1/en active Pending
- 2012-12-19 EP EP12813822.9A patent/EP2794878B1/en active Active
- 2012-12-19 RU RU2014129729A patent/RU2628703C2/en active
- 2012-12-19 CN CN201711133954.XA patent/CN107881196A/en active Pending
- 2012-12-19 BR BR112014012667A patent/BR112014012667A2/en not_active Application Discontinuation
- 2012-12-19 KR KR1020207033441A patent/KR102280111B1/en active IP Right Grant
- 2012-12-19 WO PCT/EP2012/076167 patent/WO2013092723A1/en active Application Filing
- 2012-12-19 CN CN201280062794.3A patent/CN104114701A/en active Pending
- 2012-12-19 SG SG10201601882PA patent/SG10201601882PA/en unknown
- 2012-12-19 RU RU2017127208A patent/RU2756106C2/en active
- 2012-12-19 SG SG11201403223PA patent/SG11201403223PA/en unknown
-
2015
- 2015-04-20 HK HK15103798.1A patent/HK1203546A1/en unknown
-
2016
- 2016-12-06 JP JP2016236467A patent/JP2017060519A/en active Pending
-
2018
- 2018-04-09 US US15/948,951 patent/US10882910B2/en active Active
- 2018-08-08 HK HK18110195.2A patent/HK1250743A1/en unknown
-
2019
- 2019-01-28 JP JP2019012157A patent/JP2019071903A/en active Pending
-
2020
- 2020-05-08 HR HRP20200744TT patent/HRP20200744T1/en unknown
- 2020-09-30 US US17/038,725 patent/US20210054083A1/en active Pending
-
2021
- 2021-02-16 JP JP2021022729A patent/JP7057456B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201805622QA (en) | Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides | |
AR103161A1 (en) | ANTIMIOSTATINE ANTIBODIES AND VARIANTS FC REGIONS AS WELL AS METHODS OF USE | |
HRP20180155T1 (en) | Novel anti-human ngf antibody | |
BR112012026766A2 (en) | in vitro methods for generating a heterodimeric protein, for selecting a bispecific antibody and for inhibiting growth, expression vector, host cell, heterodimeric protein, pharmaceutical composition. | |
SMT201300046B (en) | Animal models and therapeutic molecules | |
AR077369A1 (en) | METODOPARA PRODUCE Erythrocytes WITHOUT FEEDING CELLS | |
AR087608A1 (en) | BISPECIFIC MOLECULES OF ANTIGEN BINDING ACTIVITIES OF CELLS T | |
BRPI0812091A2 (en) | METHOD FOR MANUFACTURING A RECOMBINANT POLYCLONAL PROTEIN | |
MY181513A (en) | Cell culture compositions and methods for polypeptide production | |
TR201900213T4 (en) | Method of production of a polypeptide or related virus in a continuous cell culture. | |
SG10201901417UA (en) | Production of proteins in glutamine-free cell culture media | |
BR112015022529A2 (en) | cell culture media and antibody production processes | |
BR112015019341A2 (en) | ANTI-TNF-ALPHA ANTIBODY, COMPOSITION COMPRISING THE ANTIBODY, METHOD FOR PRODUCING A POPULATION OF ANTIBODIES, MAMMARY GLAND EPITHELIAL CELLS, TRANSGENIC NON-HUMAN MAMMAL, AND, MONOCLONAL ANTI-TNF ANTIBODY COMPOSITION | |
SG196836A1 (en) | Cancer stem cell population and method for production thereof | |
MX2013007650A (en) | Animal cell culturing method. | |
MX2018014043A (en) | Cell culture compositions with antioxidants and methods for polypeptide production. | |
BR112014004543A2 (en) | protein synthesis method | |
AR097805A1 (en) | TEMPERATURE CHANGE CELLS FOR THE EXPRESSION OF HIGH PERFORMANCE OF YEAST POLYPEPTIDES AND OTHER TRANSFORMED | |
WO2012125626A3 (en) | Decorin compositions and use thereof | |
MX2013011355A (en) | Recombinant polypeptide production method. | |
MY166974A (en) | Anti-human epo receptor antibodies and method of use | |
MX2016005572A (en) | Use of monensin to regulate glycosylation of recombinant proteins. | |
JP2015073480A5 (en) | ||
RU2013131429A (en) | CHO-Oma CELL STRAIN 3/1-PRODUCER OF A HUMANIZED ANTIBODY AGAINST HUMAN IMMUNOGLOBULIN AND AN ANTIBODY AGAINST HUMAN IMMUNOGLOBULIN | |
RU2016122024A (en) | CLONE OF CULTIVATED HYBRID CELLS OF ANIMAL ANIMAL MUS MUSCULUS L. RV-18 - PRODUCER OF MONOCLONAL ANTIBODIES SPECIFIC TO Rabies VIRUS RIBONUCLEOPROTEIN (N-Protein) |